Novel therapeutic concepts in multiple myeloma
Treatment of multiple myeloma (MM) has evolved greatly over the past decade, and owing to immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibition (bortezomib), patients with MM enjoy prolonged survival and improved quality of life. Use of these novel agents has improved the rate of complete remissions in MM, a parameter that has emerged as an important step towards improved survival. Bortezomib should now be considered as an established component of the induction treatment prior to autologous transplantation in younger patients. The combination of melphalan/prednisone with a novel agent is a new standard of care for elderly patients with MM. The beneficial effect of these treatment approaches is also seen in special MM populations, in particular in those with impaired renal function and high-risk cytogenetic features.
KeywordsMyeloma Complete response Thalidomide Bortezomib Lenalidomide
Unable to display preview. Download preview PDF.
- Harousseau JL, Attal M, Moreau P, Garban F, et al. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma. Combined results of the IFM 99 trials. Blood, 108: 877a, 2006 (abstract 3077)Google Scholar
- Straka C, Liebisch P, Hennemann B, Metzner B, et al. The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: the prospective randomized DSMM 2 study. Blood, 110: 138a, 2007 (abstract 446)Google Scholar
- Harousseau JL, Mathiot C, Attal M, Marit G, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation in previously untreated multiple myeloma: updated data from IFM 2005/01 trial. ASCO Proc, 26: 455s, 2008 (abstract 8505)Google Scholar
- Cavo M, Patriarca F, Tacchetti P, Galli M, et al. Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma. Blood, 110: 30a, 2007 (abstract 73)Google Scholar
- Rajkumar SV, Jacobus S, Callander N, Fonseca R, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival and outcome. ASCO Proc, 26: 455s, 2008 (abstract 8504)Google Scholar
- Facon T, Mary JH, Hulin C, Benboubker L, et al. Melphalan and prednisone plus thalidomide versus melphalan plus prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet, 370: 1209–1218, 2007PubMedCrossRefGoogle Scholar
- Hulin C, Facon T, Rodon P, Pegourie B, et al. Melphalan-prednisone-Thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with Melphalan-Prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01, Blood, 110: 31a, 2007 (abstract 75)Google Scholar
- Gulbrandsen N, Waage A, Gimsing P, Turesson I, et al. A randomized placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica, 93(Suppl 1): 84, 2008 (abstract 209)Google Scholar
- Wijermans P, Schaafsma M, van Norden Y, Ammerlaan R, et al. Melphalan+prednisone vs melphalan+prednisone+thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON. Haematologica, 93(Suppl 1): 178, 2008 (abstract 440)Google Scholar
- Ludwig H, Tothova E, Hajek R, Drach J, et al. Thalidomide-Dexamethasone vs. Melphalan-Prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Blood, 110: 163a, 2007 (abstract 529)Google Scholar
- Abdelkefi A, Ladeb S, Torjman L, Othman TB, et al. Single autologous transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood, 111: 1805–1810, 2008PubMedCrossRefGoogle Scholar
- Ludwig H, Adam Z, Greil R, Keil F, et al. Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma patients with acute renal failure. Results from an ongoing phase II study. Haematologica, 93(Suppl 1): 177, 2008, (abstract 439)Google Scholar